COMPANY RESEARCHHolds exclusive development, manufacturing, and commercialization rights for linaclotide in Japan. It is included as a regional partner for an approved, locally acting oral disulfide-constrained peptide.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Holds exclusive development, manufacturing, and commercialization rights for linaclotide in Japan. It is included as a regional partner for an approved, locally acting oral disulfide-constrained peptide.
An April 2026 announcement reports first dosing in Phase 3 setidegrasib/ASP3082 for pancreatic cancer. A Japanese official registry also records first dosing in NSCLC Phase 3 in August 2026.
The flagship protein degrader is an internally developed KRAS G12D program; a separate Cullgen collaboration also exists.
The original 2025 discovery paper resolves the KRAS(G12D)/ASP3082/VHL ternary complex, supporting VHL-dependent proteasomal degradation.
An original March 2026 NEJM Phase 1 study included 203 patients and reported weekly intravenous dosing, safety, and antitumor activity. It is not used for direct cross-study ranking.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| linaclotide / LINZESS | GC-C · Constipation-related GI indications; subject to local labeling | Approved | Acts locally in the gut; systemic oral bioavailability is not the objective |
| setidegrasib / ASP3082 | KRAS G12D · Advanced solid tumors with KRAS G12D mutations | Phase 3 | Human results reported by the source; see facts and original materials for type and quality |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Amphista announced an ASH oral presentation on AMX-883-mediated BRD9 degradation, describing disruption of hematopoietic transcriptional programs, myeloid differentiation, and reduced leukemic stem-cell frequency in experimental work. A separate abstract outlines the ongoing Phase 1 BRAMLIE study in AML and high-risk myelodysplastic syndrome. The announcement does not establish clinical efficacy for AMX-883.
Nurix announced updated Phase 1a/1b findings for its oral BTK degrader bexobrutideg (NX-5948) in relapsed or refractory CLL/SLL. The ASH presentation will include patients previously exposed to covalent BTK inhibitors and data at the recommended Phase 2 dose of 600 mg once daily. The release describes durable activity without providing numerical response rates.
A PNAS study reports RHV, a tetravalent bispecific protein designed to internalize and lysosomally degrade VCAM-1 and VEGFR on pathological vessels. The original abstract describes activity in mouse choroidal neovascularization models, including efficacy comparable to aflibercept at one-quarter of the molar dose. This is preclinical extracellular receptor degradation, distinct from an intracellular small-molecule PROTAC.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
